AstraZenecas $39B Alexion Buyout Scores EU Blessing But Still Awaits Key Nod From The UK

AstraZeneca’s $39 billion takeover of rare disease specialist Alexion has another regulatory blessing in the bag, but the pair are still holding out for a key nod from the U.K. to settle the deal. AstraZeneca on Tuesday said that the European Union has approved its acquisition of Boston-based Alexion, inching closer toward its goal of closing the deal by the end of September. The company’s Alexion buyout also has the backing from the U.S., Japan, Canada and others. But it can’t go through without the U.K.’s approval, where it’s still pending, AZ said. RELATED: AstraZeneca snaps up Alexion for $39B in a leap toward CEO's $40B revenue goal “We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines,” said AZ’s CFO Marc Dunoyer in a statement. Once completed, AstraZeneca will create a new group focused on rare diseases headquartered in Boston. Dunoyer will step into the rare disease unit's top job while retiring from AZ’s board. Meanwhile, Alexion’s current finance exec Aradhana Sarin will step into Dunoyer’s spot. The acquisition, the biopharma world’s largest in 2020, is set to boost AstraZeneca’s footprint in immunology, as well as bolster the drugmakers’ top line. AstraZeneca, which raked in $26.6 billion in 2020, has set its eyes on $40 billion by 2023. For Alexion’s part, execs have predicted the drugmaker could generate up to $10 billion in sales by 2025, up from the roughly $6 billion it bagged in 2020. The sale will eventually hand over several marketed drugs to AZ, led by blockbuster complement inhibitors Soliris and Ultomiris. RELATED: Alexion asked AstraZeneca to up its buyout offer multiple times—almost costing it a deal in the process Meanwhile, Alexion has a slew of medicines under development with the aim of bringing 10 to market by 2023. Yet some investors have worried about the company’s over-reliance on those two drugs, used to treat rare disorders such as paroxysmal nocturnal hemoglobinuria (PNH). But AZ has been encouraged by Alexion’s ability to transition a bulk of PNH patients from Soliris to Ultomiris in less than two years. The U.K.-based pharma also hopes the complement system can be targeted for more common diseases in the fields of oncology, neurology and respiratory. On top of Alexion’s C5 franchise, AZ also sees promise in Alexion’s pipeline, which includes treatments for Wilson disease, geographic atrophy and renal diseases, Dunoyer said on a call with analysts earlier this year.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!